首页 › 基金 › Uniplan Investment Counsel, Inc. › LGND
Uniplan Investment Counsel, Inc. 对 LGND 的持仓历史
LIGAND PHARMACEUTICALS INC · 医疗保健
Uniplan Investment Counsel, Inc. 在 Q3 2026 的 13F 申报中披露持有 LGND(LIGAND PHARMACEUTICALS INC)35,176 股,市值约 US$11.0M,约占其申报组合的 1.08%,在其申报持仓中市值排名第 20 位。 Uniplan Investment Counsel, Inc. 最近 11 个申报季度中有 11 个季度披露了 LGND 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Uniplan Investment Counsel, Inc. 对 LGND 的持仓演变
Uniplan Investment Counsel, Inc. 于 Q1 2024 首次披露 LGND 持仓:41,201 股(约 US$3.0M)。 该持仓在 Q3 2026 达到峰值 35,176 股,市值约 US$11.0M。 在 11 次申报中,Uniplan Investment Counsel, Inc. 5 次增持、4 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 35,176 股、市值约 US$11.0M,环比增持 927 股。。 持仓曾出现大幅变动:Q4 2024 增持约 28% (随后一个季度股价下跌 2%)、Q3 2025 减持约 33% (随后一个季度股价上涨 7%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 41.20K | $3.01M | 新进 |
| Q2 2024 | 49.62K | $4.18M | 增持 |
| Q3 2024 | 53.10K | $5.32M | 增持 |
| Q4 2024 | 68.16K | $7.30M | 增持 |
| Q1 2025 | 68.79K | $7.23M | 增持 |
| Q2 2025 | 62.95K | $7.16M | 减持 |
| Q3 2025 | 42.18K | $7.47M | 减持 |
| Q4 2025 | 42.36K | $8.01M | 持有 |
| Q1 2026 | 40.19K | $8.02M | 减持 |
| Q2 2026 | 34.25K | $10.83M | 减持 |
| Q3 2026 | 35.18K | $10.99M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 LGND 与 13F 数据
LGND(LIGAND PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 52 只申报持有 LGND,申报仓位最大的包括:CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$139.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 LGND 的基金
- CONGRESS ASSET MANAGEMENT CO 658.56K 股 · $205.71M · Q3 2026
- Chicago Capital, LLC 551.23K 股 · $172.19M · Q3 2026
- Stephens Investment Management Group LLC 446.14K 股 · $139.36M · Q3 2026
- RICE HALL JAMES & ASSOCIATES, LLC 270.05K 股 · $85.36M · Q2 2026
- WOLVERINE ASSET MANAGEMENT LLC 50.37M 股 · $84.80M · Q3 2026
- GW&K Investment Management, LLC 241.76K 股 · $75.52M · Q3 2026
- NEXT CENTURY GROWTH INVESTORS LLC 192.39K 股 · $60.10M · Q3 2026
- Ranger Investment Management, L.P. 185.65K 股 · $57.99M · Q3 2026
- ASHFORD CAPITAL MANAGEMENT INC 170.24K 股 · $53.81M · Q2 2026
- Private Capital Management, LLC 166.02K 股 · $52.48M · Q2 2026
- Granahan Investment Management, LLC 147.23K 股 · $46.54M · Q2 2026
- Penn Capital Management Company, LLC 98.75K 股 · $30.88M · Q3 2026
更多关于 Uniplan Investment Counsel, Inc.
常见问题
How long has Uniplan Investment Counsel, Inc. held LGND?
Uniplan Investment Counsel, Inc. has disclosed LGND holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Uniplan Investment Counsel, Inc.'s current position in LGND?
As of Q3 2026, Uniplan Investment Counsel, Inc. holds 35.18K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $10.99M, representing 1.08% of its reported portfolio and ranking #20.
Has Uniplan Investment Counsel, Inc. been buying or selling LGND?
In the latest 13F filing (Q3 2026), Uniplan Investment Counsel, Inc. increased its position in LGND. The position peaked in Q3 2026 at 35.18K shares.
Which other funds hold LGND?
Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.